Search clinical trials for: Deferoxamine Mesylate

Total 1695 results

Beth Israel Deaconess Medical Center
Medical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaborators

Completed

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Intracerebral Hemorrhage

United States, Canada
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Terminated

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Massachusetts General Hospital; National... and other collaborators

Completed

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage (DFO In ICH)

Intracerebral Hemorrhage

United States
Brigham and Women's Hospital
Dr. Jeffrey Thomas Stroke Shield Foundation

Terminated

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Subarachnoid Hemorrhage

United States
Capital Medical University
Peking University First Hospital; Peking University People's Hospital; Beijing... and other collaborators

Unknown

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Intracerebral Hemorrhage

China
Brigham and Women's Hospital
National Institute on Aging (NIA)

Completed

Modulation of Cerebral Blood Flow Using Iron Chelators (DFO)

Stroke | Problem of Aging

United States
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaborators

Terminated

High-Dose Deferoxamine in Intracerebral Hemorrhage (HI-DEF)

Intracerebral Hemorrhage

United States, Canada
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Novartis Pharmaceuticals

Completed

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload (CORDELIA)

Transfusional Hemosiderosis | Transfusional Iron Overload

Taiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
Memorial Sloan Kettering Cancer Center
Center for Experimental Therapeutics; F.M. KIRBY FOUNDATION

Recruiting

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Leptomeningeal Metastases

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Hematologic Diseases | Iron Overload | Hemoglobinopathies | Thalassemia | Beta-Thalassemia | Hemochromatosis | Anemia (Iron-Loading)
Elliott Vichinsky

Completed

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Iron Overload | Thalassemia

United States
TauTona Group

Withdrawn

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment (D-SCOUT)

Sickle Cell Disease | Chronic Cutaneous Ulcer

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload (HYPERION)

Cardiac Iron Overload

Taiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
Novartis Pharmaceuticals

Completed

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Anemia, Sickle Cell

United States
Novartis Pharmaceuticals

Completed

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Beta-Thalassemia

United States
Ain Shams University

Unknown

Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)

Beta-thalassemia | Serum Ferritin | Iron Chelation Therapy

Egypt
Ospedale Microcitemico
Azienda Sanitaria Locale di Cagliari

Completed

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major (DFODFPTM)

Iron Overload | Cardiomyopathy

Italy
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
Sun Yat-sen University

Recruiting

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

China
ApoPharma

Completed

Efficacy Study in Removing Excess Iron From the Heart

Hemosiderosis | Thalassemia Major

Greece, Italy
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Cardiac Iron Overload | Transfusion-dependent β-thalassemia Patients

Greece
University of Bologna

Completed

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

Italy
Genzyme, a Sanofi Company

Completed

Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

Beta-Thalassemia

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
Jinan Military General Hospital

Recruiting

The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

China
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Refractory Desmoplastic Small Round Cell Tumors

Italy
Radboud University Medical Center

Not yet recruiting

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine (MIRAGE)

Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Chronic Pulmonary Aspergillosis
Karolinska University Hospital

Recruiting

Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes (DESIRED)

Diabetes Mellitus, Type 1

Sweden
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Azienda Ospedaliera V. Cervello

Completed

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP (SEQDFPDFO)

Beta-Thalassemia | Thalassemia Major

Italy
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom
Merz Pharmaceuticals GmbH

Completed

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Healthy

Germany
Nanjing First Hospital, Nanjing Medical University

Enrolling by invitation

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Main Heading (Descriptor) Terms

China
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Eisai Co., Ltd.

Completed

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Soft Tissue Sarcoma

Japan
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus (EASE)

Subjective Tinnitus

Germany, Portugal, Spain, United Kingdom, Austria
Eisai Inc.

Completed

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Cancer

Netherlands

Search clinical trials for: Deferoxamine Mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations